Samuel Rosner

3.3k total citations
33 papers, 412 citations indexed

About

Samuel Rosner is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Samuel Rosner has authored 33 papers receiving a total of 412 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 13 papers in Pulmonary and Respiratory Medicine and 10 papers in Surgery. Recurrent topics in Samuel Rosner's work include Cancer Immunotherapy and Biomarkers (12 papers), Lung Cancer Treatments and Mutations (10 papers) and Lung Cancer Research Studies (4 papers). Samuel Rosner is often cited by papers focused on Cancer Immunotherapy and Biomarkers (12 papers), Lung Cancer Treatments and Mutations (10 papers) and Lung Cancer Research Studies (4 papers). Samuel Rosner collaborates with scholars based in United States, Spain and Australia. Samuel Rosner's co-authors include Patrick M. Forde, Joshua E. Reuss, Michael A. Postow, Chen Hu, Margaret K. Callahan, Katherine S. Panageas, Jedd D. Wolchok, Mary Sue Brady, Paul B. Chapman and Allison Betof Warner and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Samuel Rosner

29 papers receiving 393 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Samuel Rosner United States 10 257 147 87 73 46 33 412
Mohammed Lilo United States 11 318 1.2× 86 0.6× 124 1.4× 72 1.0× 131 2.8× 19 500
Sonia M. Kheir United States 8 159 0.6× 37 0.3× 30 0.3× 90 1.2× 42 0.9× 12 307
John Panelos Italy 10 218 0.8× 123 0.8× 43 0.5× 39 0.5× 160 3.5× 18 487
Vishwajith Sridharan United States 8 246 1.0× 41 0.3× 72 0.8× 92 1.3× 23 0.5× 16 305
Yukiko Teramoto Japan 10 406 1.6× 64 0.4× 102 1.2× 41 0.6× 156 3.4× 37 514
Lisa Anderson United States 12 113 0.4× 30 0.2× 30 0.3× 85 1.2× 77 1.7× 22 375
A. Vilalta Spain 10 194 0.8× 31 0.2× 79 0.9× 22 0.3× 82 1.8× 26 300
Megan D. Schollenberger United States 8 289 1.1× 36 0.2× 72 0.8× 15 0.2× 107 2.3× 15 390
Michael Sidiropoulos United States 11 138 0.5× 44 0.3× 21 0.2× 24 0.3× 96 2.1× 23 400
Mackenzie Daly United States 13 245 1.0× 151 1.0× 26 0.3× 218 3.0× 103 2.2× 37 580

Countries citing papers authored by Samuel Rosner

Since Specialization
Citations

This map shows the geographic impact of Samuel Rosner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Samuel Rosner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Samuel Rosner more than expected).

Fields of papers citing papers by Samuel Rosner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Samuel Rosner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Samuel Rosner. The network helps show where Samuel Rosner may publish in the future.

Co-authorship network of co-authors of Samuel Rosner

This figure shows the co-authorship network connecting the top 25 collaborators of Samuel Rosner. A scholar is included among the top collaborators of Samuel Rosner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Samuel Rosner. Samuel Rosner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rosner, Samuel, Joshua E. Reuss, Marianna Zahurak, et al.. (2023). Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non–Small Cell Lung Cancer. Clinical Cancer Research. 29(4). 705–710. 44 indexed citations
2.
Sanber, Khaled, Samuel Rosner, Patrick M. Forde, & Kristen A. Marrone. (2023). Neoadjuvant Immunotherapy for Non-Small Cell Lung Cancer. BioDrugs. 37(6). 775–791. 4 indexed citations
3.
Rosner, Samuel, et al.. (2023). Antibody-Drug Conjugates for Lung Cancer: Payloads and Progress. American Society of Clinical Oncology Educational Book. 43(43). e389968–e389968. 20 indexed citations
4.
Marrone, Kristen A., et al.. (2023). Adagrasib: a novel inhibitor for KRAS G12C -mutated non-small-cell lung cancer. Future Oncology. 19(15). 1037–1051. 4 indexed citations
5.
Alden, Stephanie, Charuta C. Palsuledesai, Adham Jurdi, et al.. (2022). Post-operative ctDNA monitoring in stage I colon cancer: A case report. Frontiers in Oncology. 12. 1074786–1074786. 1 indexed citations
6.
Rosner, Samuel & Patrick M. Forde. (2022). Chemotherapy + PD-1/PD-L1 Blockade Should Be the Preferred Option in the Neoadjuvant Therapy of NSCLC. Journal of Thoracic Oncology. 17(4). 503–509. 6 indexed citations
7.
8.
Rosner, Samuel, Joshua E. Reuss, Marianna Zahurak, et al.. (2022). Neoadjuvant nivolumab in early-stage non–small cell lung cancer (NSCLC): Five-year outcomes.. Journal of Clinical Oncology. 40(16_suppl). 8537–8537. 9 indexed citations
9.
Hussaini, S. M. Qasim, Samuel Rosner, Erica C. Nakajima, et al.. (2022). Innovation in recruitment and curricular design for diversity, equity, and inclusion (DEI) education for hematology-oncology (HO) trainees.. Journal of Clinical Oncology. 40(28_suppl). 179–179. 1 indexed citations
10.
Al‐Mufti, Fawaz, Gurmeen Kaur, Krishna Amuluru, et al.. (2021). Middle Meningeal Artery Embolization Using Combined Particle Embolization and n-BCA with the Dextrose 5% in Water Push Technique for Chronic Subdural Hematomas: A Prospective Safety and Feasibility Study. American Journal of Neuroradiology. 42(5). 916–920. 21 indexed citations
11.
LoPiccolo, Jaclyn, Megan D. Schollenberger, Samuel Rosner, et al.. (2019). Rescue therapy for patients with anti-PD-1-refractory Merkel cell carcinoma: a multicenter, retrospective case series. Journal for ImmunoTherapy of Cancer. 7(1). 170–170. 41 indexed citations
12.
Rosner, Samuel, Alexander N. Shoushtari, Claire F. Friedman, et al.. (2018). Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma. Cancer Medicine. 7(3). 690–697. 91 indexed citations
13.
Rosner, Samuel, Joshua E. Reuss, & Patrick M. Forde. (2018). PD-1 Blockade in Early-Stage Lung Cancer. Annual Review of Medicine. 70(1). 425–435. 29 indexed citations
14.
Rosner, Samuel, Filiz Şen, & Michael A. Postow. (2017). Response after treatment with pembrolizumab in a patient with myelophthisis due to melanoma: the role of checkpoint inhibition in the bone. Journal for ImmunoTherapy of Cancer. 5(1). 34–34. 6 indexed citations
15.
Rosner, Samuel, Ellen M. Ginzler, & Herbert S. Diamond. (1981). Spontaneous rupture of splenic artery and cerebrovascular accident; with systemic lupus erythematosus.. PubMed. 81(6). 940–2.
16.
Nathan, Hílel & Samuel Rosner. (1977). Multiple meningeal diverticula and cysts associated with duplications of the sheaths of spinal nerve posterior roots. Journal of neurosurgery. 47(1). 68–72. 9 indexed citations
17.
Rosner, Samuel. (1975). Immunological enhancement of chemotherapy in advanced brain cancer.. PubMed. 21(1-4). 126–32. 1 indexed citations
18.
Rosner, Samuel. (1954). Venous angioma; a cause of cerebral palsy.. PubMed. 22(1 1). 94–7.
19.
Rosner, Samuel. (1953). Neonatal bleeding and cerebral birth palsy.. PubMed. 19(4). 494–504. 1 indexed citations
20.
Rosner, Samuel. (1951). NEUROSURGICAL OBSERVATIONS IN THE MULTIPLE SCLEROSIS SYNDROME. The Journal of Nervous and Mental Disease. 114(1). 511–518. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mohammed Lilo Breakdown of academic impact, for papers by Sonia M. Kheir Breakdown of academic impact, for papers by John Panelos Breakdown of academic impact, for papers by Vishwajith Sridharan Breakdown of academic impact, for papers by Yukiko Teramoto Breakdown of academic impact, for papers by Lisa Anderson Breakdown of academic impact, for papers by A. Vilalta Breakdown of academic impact, for papers by Megan D. Schollenberger Breakdown of academic impact, for papers by Michael Sidiropoulos Breakdown of academic impact, for papers by Mackenzie Daly
Rankless by CCL
2026